GH Research's Mebufotenin Therapy GH001 Shows 73% Remission Rate in Treatment-Resistant Depression
核心洞察
GH Research's lead candidate GH001 achieved a highly significant 15.5-point reduction in depression (搜索) scores compared to placebo on Day 8 in its Phase 2b trial (p<0.0001).
The open-label extension demonstrated a 73% remission rate at 6 months with no treatment-related serious adverse events or suicidal behaviors during the full trial duration.
The company continues to work with FDA to resolve the remaining clinical hold issue and expects to initiate global pivotal trials in 2026.
GH Research PLC reported compelling long-term efficacy data for its novel mebufotenin therapy GH001 in treatment-resistant depression (搜索), with the open-label extension of its Phase 2b trial demonstrating a 73% remission rate at 6 months. The Dublin-based clinical-stage biopharmaceutical company announced these results alongside its third quarter 2025 financial results, highlighting the potential for a transformative treatment approach in depression (搜索) care.
Phase 2b Trial Delivers Strong Primary Endpoint Results
The company's Phase 2b clinical trial (GH001-TRD-201) met its primary endpoint with a highly significant placebo-adjusted reduction of 15.5 points in Montgomery-Åsberg Depression (搜索) Rating Scale (MADRS) total score on Day 8 (p<0.0001). This substantial improvement in depression symptoms was achieved through GH001's proprietary inhalation delivery system for mebufotenin administration.
The full analysis of the open-label extension confirmed sustained therapeutic benefits, with patients achieving a 73% remission rate at 6 months while requiring only infrequent treatment visits and no mandated psychotherapeutic intervention. This durability of response represents a significant advancement in treatment-resistant depression (搜索) management, where patients typically cycle through multiple unsuccessful therapies.
Safety Profile Supports Continued Development
Throughout the complete 6-month trial duration, GH001 demonstrated a favorable safety profile with no treatment-related serious adverse events reported. Notably, no treatment-emergent events of suicidal intent or suicidal behavior occurred during the study period, addressing a critical safety concern in depression (搜索) treatment development.
Professor Wiesław J. Cubała, MD, PhD, from the Department of Psychiatry at the Medical University of Gdańsk (搜索), presented the long-term safety and efficacy data from the open-label extension at the Novel Therapies Symposium during the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam in October 2025. Additional poster presentations at the conference detailed safety and tolerability data as well as psychoactive effects of GH001 in treatment-resistant depression (搜索) patients.
Regulatory Progress and Clinical Hold Status
GH Research continues to engage with the U.S. Food and Drug Administration regarding its Investigational New Drug Application (IND) for GH001. In July 2025, the company received communication from the FDA relating to its complete response to the clinical hold, with only one hold topic remaining. The company is actively working with experts to address this remaining regulatory requirement.
Despite the ongoing clinical hold, GH Research maintains its expectation to initiate a global pivotal program in 2026, positioning the company to advance toward potential regulatory approval for this novel therapeutic approach.
Financial Position Supports Development Timeline
The company reported cash, cash equivalents, and marketable securities of $293.9 million as of September 30, 2025, representing a significant increase from $182.6 million at December 31, 2024. This strong financial position provides substantial runway to support continued development activities and the planned global pivotal program.
Research and development expenses increased to $10.6 million for the third quarter of 2025, compared to $8.4 million in the same quarter of 2024, primarily due to increased technical development activities and employee expenses. The company reported a net loss of $14.0 million, or $0.23 per share, for the quarter.
Expanding Mebufotenin Pipeline
Beyond GH001, GH Research is developing GH002, a mebufotenin product candidate formulated for intravenous administration. The company has completed a Phase 1 trial of GH002 in healthy volunteers, expanding the potential delivery options for this novel therapeutic class.
The mebufotenin-based approach represents a differentiated mechanism in the treatment-resistant depression (搜索) landscape, with GH Research positioning these therapies as potentially practice-changing treatments that could transform current depression (搜索) care paradigms.